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patients was CNY159722, in patients with peritoneal dialysis for CNY96739; In 
CKD patients, the presence of acute onset of CVD events, no acute CVD events and 
patients without CVD showed that the medical costs for three groups of median 
were CNY38211.9 (11 685.1~73 358.7), ll061.4 (3 809.0 ~ 23 241.0) and 13678.7 (456.5 
~36 995.3).The indirect economic burden included loss of time and property in 
patients because of illness. In hemodialysis patients, per capita annual indirect 
costs were CNY27531.2. In peritoneal dialysis patients, per capita annual indirect 
costs were CNY96739.6. ConClusions: Economic Burden of chronic kidney dis-
ease patients with hyperphosphatemia is “catastrophic expenses” for the vast 
majority of the patient’s families. In order to protect the interests of patients, 
health insurance in China needs to constantly change the protection’s structures, 
improve the ability of insurance and expand the range of coverage.
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objeCtives: In France, health insurance coverage is mandatory for all individuals. 
Administrative information necessary for the reimbursement of healthcare costs by 
French National Health Insurance is recorded in the Vitale Card that patients use in 
every step of their care. Since 2013 this information is available in claims database 
including for each patient the comprehensive history of his/her health care expen-
ditures. This database can be accessed alone or through a linkage to an electronic 
medical record database. The objective of this study was to evaluate the usefulness 
of this newly accessible information in assessing treatment cost of Benign Prostatic 
Hyperplasia (BPH) Methods: Patients with a first prescription of BPH treatment and 
enrolled 1 year pre-/post index, were identified in a primary care electronic medical 
record database (CSD longitudinal patients database). Patients’ characteristics and 
medical history were analyzed. Healthcare costs, exclusively related to BPH, were 
retrieved from the Health Economic Analysis Database and evaluated according to 
healthcare services: 1) Drugs delivered, both for BPH and for urinary tract infection, 
2) Visits to physicians, 3) Laboratory and radiological exams, 4) medical and surgical 
procedures, 5) Hospitalizations. All health expenses were assessed from the payer’s 
perspective Results: A total of 16 893 patients were identified of whom 4 315 (24.5%) 
were treated with phytotherapeutic and 12758 (75.5%) with allopathic treatments. 
Median age was 66 years, they had been diagnosed for less than 1 year (0.87 year), 45.9% 
had hypertension, 31.6% had dyslipidemia and 16.3% had type 2 diabetes. Total cost 
HBP treatment was averagely about Euros 450 per patients/ per year. ConClusions: 
Estimating costs related to therapies is an increasingly mandatory exercise for phar-
maceutical companies. The combination of EMR and claims allows a relevant and 
accurate analysis of health care costs from the payer’ point of view.
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objeCtives: To conduct the “cost of illness” analysis of chronic kidney disease (CKD) 
based on the entire population of the Russian Federation. Methods: Information 
retrieval was in the public domain. Pharmacoeconomic analysis method “cost of 
illness” was used. Direct and indirect cost analysis was also performed. Results: 
Analysis of found epidemiological data revealed that, in fact, in the Russian Federation 
the only available epidemiological information is on the later stages of CKD (accom-
panied by the appointment of renal replacement therapy). Based on that during “cost 
of illness” analysis at the population level we have extrapolated data on the distri-
bution of patients by stage of CKD available in the article Lori A. et al. 2011. Then 
the cost of various stages of CKD (including direct and indirect costs) per patient 
was calculated. At the final stage the economic burden of CKD on the entire patient 
population in the Russian Federation was determined. The total cost for all patients 
with CKD who are in stages with I to V in the year were: CKD I – 1157758914 $, CKD 
II – 1348201542 $, CKD III – 2622796532 $, CKD IV – 218480559 $, CKD V (not receiving 
renal replacement therapy) – 890038600 $, CKD V (on hemodialysis) - 462938674 $, 
CKD V (on peritoneal dialysis) - 50407252 $, CKD V (exposed of the kidney transplant) 
- 79916759 $. Thus, the total economic burden of all stages of CKD in country scale 
was 6830521313 $ per year (1 $ = 66,0983). ConClusions: “Cost of illness” analysis 
showed the economic burden of CKD on the entire patient population of the Russian 
Federation and found that the major portion of the cost appears in the early stages 
of CKD.
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objeCtives: Cost unaffordability is one of the major reasons for the deprived qual-
ity of life and increased mortality in chronic kidney disease (CKD) patients especially 
in patients on dialysis. However, very limited data is available on CKD cost of illness 
(COI). This study was carried out to estimate the cost of illness in the patients of 
CKD. Methods: This cross sectional study was carried at a renal clinic of a tertiary 
care hospital over a period of six months. COI was estimated as the sum of the direct 
and indirect cost involved. Direct cost was divided into direct medical and direct 
non-medical cost. Direct medical cost included the acquisition cost and ancillary 
cost. Direct non-medical cost included the cost of transportation & food. Indirect 
cost included the loss of productivity as a result of absence from work by patients 
and care givers. Five stages of CKD patients were divided into two groups (G1-G4, and 
G5), according to KDIGO guidelines. Costs were estimated in terms of Indian national 
rupee (INR; IUSD~INR62). Results: A total of 122 patients were included in the 
in prescribing multiple drug classes may improve care for men with substan-
tial storage symptoms that have not been adequately addressed by α -blocker 
monotherapy.
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objeCtives: While short-term kidney graft survival has gradually improved over 
time, improvements in long-term graft survival have been more modest. One key 
clinical factor limiting improved long-term outcomes is antibody-mediated rejec-
tion (AbMR). Recent data suggest that AbMR incidence is higher in non-adherent 
patients; a factor that can be improved by reducing pill burden. The aim of the 
present study was to model the incidence and economic consequences of graft loss 
and AbMR with once-daily, prolonged-release (PR) tacrolimus versus twice-daily, 
immediate-release (IR) tacrolimus in the UK setting. Methods: A combined deci-
sion tree and Markov model was developed to estimate incidence of graft failure, 
AbMR and mortality in renal transplant recipients taking PR versus IR tacroli-
mus. Underlying rates of graft failure and mortality were derived from UK-specific 
sources. Proportions of patients adherent to once- and twice-daily tacrolimus were 
taken from a recent randomized trial. Relative risks of graft failure and AbMR were 
taken from a separate prospective analysis of 315 patients. Cost data were taken 
from the British National Formulary and NHS reference costs and reported in 2014 
pounds sterling. Results: Switching patients from IR to PR tacrolimus would 
result in projected cost savings of GBP 4,862 per patient over five years, translat-
ing to savings of GBP 486,200 in a hypothetical 100-patient cohort. Mean absolute 
per-patient costs with PR tacrolimus were projected to be GBP 40,974 versus GBP 
45,836 with IR, with the largest saving arising from reduced dialysis costs, fol-
lowed by reduced pharmacy and AbMR treatment costs. ConClusions: Modeling 
analysis showed that using PR tacrolimus in place of IR in UK renal transplant 
recipients was associated with lower pharmacy, dialysis and AbMR treatment 
costs, with the reduction in AbMR and dialysis costs being driven by improved 
adherence to PR tacrolimus and the consequent reductions in graft loss and onset 
of AbMR.
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objeCtives: Antibody mediated rejection (AMR) is a major cause of graft failure 
following kidney transplantation (KTx). No agents are currently approved for preven-
tion or management of AMR. Current strategies include plasmapheresis (PP) and 
intravenous immunoglobulin. Economic burden of AMR in the real-world clinical 
setting has not been studied. Methods: Eligible patients (age ≥ 18 years) had 
a record of a hospitalization in the Premier database between January, 2006 and 
December, 2013 and were recipients of a kidney-only transplant. We used the occur-
rence of PP up to 90 days post-transplant as an indicator of AMR. A propensity 
score-matched cohort of No AMR, having at least 2 outpatient follow up visits within 
90 days post-KTx without evidence of PP, was used for comparative analyses. Total 
number of days in the hospital and total hospital costs (US dollars) aggregated over 
the hospital visits were compared between matched cohorts using a gamma log 
link regression model. Model-based (mean) estimates are reported for AMR versus 
No AMR. Results: A total of n= 215 patients with AMR (mean age was 47 ± 14 years, 
51% were male, 45% were recipients of a living donor, 19% had a previous KTx and 
15% had a history of diabetes) were matched to n= 215 No AMR patients. Mean 
total number of days in the hospital for the AMR cohort was 20 days compared to 
11 days for the No AMR cohort (p< 0.0001). Total hospital costs were 50% higher in 
the AMR cohort compared to the No AMR cohort (Mean = $135,172 versus $90,527, 
respectively; p< 0.0001), irrespective of donor type (AMR match cohort X Donor type 
(living or deceased donor) interaction: p= 0.748). ConClusions: AMR is associated 
with significant economic challenges early post-KTx and is costly to the healthcare 
system. Therapies targeted at preventing and treating AMR have important eco-
nomic and clinical implications.
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objeCtives: Hyperphosphatemia in chronic kidney disease is a common com-
plication in patients with end-stage renal. This paper reviews the researches 
which were done for China’s current economic burden of hyperphosphatemia in 
chronic kidney disease. Methods: Using “chronic kidney disease”, “hyperphos-
phatemia in chronic kidney disease” and “economic burden” are as the key words 
to choose articles in PUBMED and Chinese journals. At the same time, the data 
of dialysis patients with CKD stages in 2012 from Beijing, Shanghai, Chengdu, 
Guangzhou and the databases of national urban basic medical insurance in 2010 
are analyzed. Results: Economic burden of chronic kidney disease in patients 
with hyperphosphatemia is divided into direct and indirect costs. The direct eco-
nomic burden includes dialysis treatment and hospital costs, drug costs and car-
diovascular complications’ costs. Among them, dialysis treatment and hospital 
costs (including drug costs), per capita annual economic burden in hemodialysis 
